Anika Therapeutics (ANIK) Misses Q4 EPS by 10c
Tweet
Share
E-mailGet Alerts ANIK Hot Sheet
Price: $20.87 -1.09%
Financial Fact:
Licensing, milestone and contract revenue: 6K
Today's EPS Names:
RIBT, INLB, FTXP, More
Financial Fact:
Licensing, milestone and contract revenue: 6K
Today's EPS Names:
RIBT, INLB, FTXP, More
Join SI Premium – FREE
Anika Therapeutics (NASDAQ: ANIK) reported Q4 EPS of ($0.34), $0.10 worse than the analyst estimate of ($0.24). Revenue for the quarter came in at $39.62 million versus the consensus estimate of $37.71 million.
For earnings history and earnings-related data on Anika Therapeutics (ANIK) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- PG&E downgraded by Wells Fargo, BMO as California wildfire reform falls short
- C1 Fund reports portfolio growth and share repurchase activity
- BofA turns S&P 500 signals from red to yellow: What to buy now
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
